Lung cancer - Time to move on from chemotherapy

New England Journal of Medicine

Volumn 346, Issue 2, 2002, Pages 126-128

  Carney, Desmond N ^a  

^a MATER MISERICORDIAE UNIVERSITY HOSPITAL   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BETA CAROTENE; CARBOPLATIN; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; ETOPOSIDE; GEFITINIB; RETINOL; TRASTUZUMAB; UNCLASSIFIED DRUG;

CANCER COMBINATION CHEMOTHERAPY; CANCER PREVENTION; CANCER RISK; CANCER SCREENING; CANCER SURVIVAL; CLINICAL TRIAL; DRUG INDICATION; DRUG MECHANISM; EDITORIAL; GENE MUTATION; HUMAN; LUNG CARCINOMA; PRIORITY JOURNAL; TREATMENT OUTCOME; TREATMENT PLANNING;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SMALL CELL; CISPLATIN; ETOPOSIDE; HUMANS; LUNG NEOPLASMS; SMOKING; SURVIVAL RATE;

EID: 0037050355     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM200201103460211     Document Type: Editorial

References (18)

1. Cancer statistics, 2001
2. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer
3. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer
4. Twenty years of phase III trials for patients with extensive-stage small-cell lung cancer: Perceptible progress
5. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: A Southwest Oncology Group trial
6. A randomized trial of the four most active regimens for metastatic non-small-cell lung cancer
7. Prognostic factors for survival in advanced non-small-cell lung cancer: Univariate and multivariate analyses including recursive partitioning and amalgamation algorithms in 1,052 patients
8. Reducing tobacco consumption in California: Development of a statewide anti-tobacco use campaign
9. Early lung cancer action project: Overall design and findings from baseline screening
10. Lung cancer screening: Improving survival but no reduction in deaths - The role of over diagnosis
11. Differential frequencies of p16(INK4a) promoter hypermethylation, p53 mutation, and K-ras mutation in exfoliative material mark the development of lung cancer in symptomatic chronic smokers
12. Detection of microsatellite alterations in plasma DNA of non-small cell lung cancer patients: A prospect for early diagnosis
13. Fluorescence versus white-light bronchoscopy for detection of preneoplastic lesions: A randomized study
14. Lung cancer chemoprevention. An integrated approach
15. The effects of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers
16. Targeting the epidermal growth factor receptor: A clinical reality
17. Phase I/II trial of ISIS 3521 an antisense inhibitor ofPKC-alpha, with carboplatin and paclitaxel in non-small cell lung cancer
18. A phase II trial of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor OS1-774 following platinum based chemotherapy in patients with advanced, EGFR expressing non-small cell lung cancer